These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30543676)

  • 1. Bin-CE: A comprehensive web application to decide upon the best set of outcomes to be combined in a binary composite endpoint.
    Marsal JR; Ferreira-González I; Ribera A; Oristrell G; Pijoan JI; García-Dorado D
    PLoS One; 2018; 13(12):e0209000. PubMed ID: 30543676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of a Binary Composite Endpoint and Sample Size Requirement: Influence of Endpoints Overlap.
    Marsal JR; Ferreira-González I; Bertran S; Ribera A; Permanyer-Miralda G; García-Dorado D; Gómez G
    Am J Epidemiol; 2017 May; 185(9):832-841. PubMed ID: 28402501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
    Roig MB; Melis GG; Posch M; Koenig F
    Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of composite binary endpoints in clinical trials.
    Bofill Roig M; Gómez Melis G
    Biom J; 2018 Mar; 60(2):246-261. PubMed ID: 29023990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components.
    Bofill Roig M; Gómez Melis G
    Stat Med; 2019 May; 38(11):1935-1956. PubMed ID: 30637797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size determination in clinical trials with multiple co-primary binary endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    Stat Med; 2010 Sep; 29(21):2169-79. PubMed ID: 20687162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Composite endpoints.
    Palileo-Villanueva LM; Dans AL
    J Clin Epidemiol; 2020 Dec; 128():157-158. PubMed ID: 32739473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights.
    Marsal JR; Urreta-Barallobre I; Ubeda-Carrillo M; Osorio D; Lumbreras B; Lora D; Fernández-Felix BM; Oristrell G; Ródenas-Alesina E; Herrador L; Ballesteros M; Zamora J; Pijoan JI; Ribera A; Ferreira-González I
    Trials; 2022 Dec; 23(1):1037. PubMed ID: 36539800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints.
    McMenamin ME; Barrett JK; Berglind A; Wason JMS
    Stat Med; 2022 Jun; 41(13):2303-2316. PubMed ID: 35199380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistency-ensured parametric tests for critical events of composite endpoints.
    Huque MF; Alosh M; Guerra M
    J Biopharm Stat; 2018; 28(1):82-98. PubMed ID: 29144871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of a binary composite endpoint with missing data in components.
    Quan H; Zhang D; Zhang J; Devlamynck L
    Stat Med; 2007 Nov; 26(26):4703-18. PubMed ID: 17431851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
    Bakal JA; Westerhout CM; Armstrong PW
    Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Easily applicable multiple testing procedures to improve the interpretation of clinical trials with composite endpoints.
    Schüler S; Mucha A; Doherty P; Kieser M; Rauch G
    Int J Cardiol; 2014 Jul; 175(1):126-32. PubMed ID: 24861257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous inference of a binary composite endpoint and its components.
    Große Ruse M; Ritz C; Hothorn LA
    J Biopharm Stat; 2017; 27(1):56-69. PubMed ID: 26881805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical grand rounds: design and analysis of studies with binary- event composite endpoints: guidelines for anesthesia research.
    Mascha EJ; Sessler DI
    Anesth Analg; 2011 Jun; 112(6):1461-71. PubMed ID: 21543784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
    Huque MF; Alosh M; Bhore R
    J Biopharm Stat; 2011 Jul; 21(4):610-34. PubMed ID: 21516560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinded assessment of treatment effects for survival endpoint in an ongoing trial.
    Xie J; Quan H; Zhang J
    Pharm Stat; 2012; 11(3):204-13. PubMed ID: 22337644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of multiple endpoint dependency on Q and I(2) in meta-analysis.
    Thompson CG; Becker BJ
    Res Synth Methods; 2014 Sep; 5(3):235-53. PubMed ID: 26052849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.
    Dong G; Li D; Ballerstedt S; Vandemeulebroecke M
    Pharm Stat; 2016 Sep; 15(5):430-7. PubMed ID: 27485522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.